Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of drotrecogin alfa (activated) in severe sepsis
ISRCTN74215569Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 1998
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Xigris with Placebo (2 arms). Started Jul 1998; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on ISRCTN74215569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74215569.